Q2 2022 SCYNEXIS Inc Earnings Call

Welcome to the Viovid Conference Center. The next available conference specialist will be with you momentarily. Conference Center, have your first and last name. First name David, last name Brown. And your next company. Aera, A-I-E-R-A. Always calm for joining. For Sky Nexus. Okay. Thank you for joining the conference. Please record the requested information when prompted. Please speak slowly and clearly so that we can more accurately record your information. If no information is recorded or you are having difficulty, please stay on the line for operator assistance. After the tone, please record and spell your email address. Then press the pound key to continue. David at Aera dot com. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you.

So.

presal be ly. The five con cent conferen special will be ly ingi ING Act. Thank joining the conference ase record recordquested information Ed and more record information, information recorded having ase oper after ase record pres. To continue, Thank generment the Ning and to the second quar 20 twent con call exp's 4, four ation one the conferens four mind the conference recorded the conferen ication and relation Thank one and today conference second quarter 20, 20 financial Su Corp day four me remind incl four looking statements based cur pectations including ments cering finci, the future expect, ation financi and operation formments, strate ment Su exp four statements ase refer our with securee exchange missation includ our and 4, four year included and ion facers and another docum securee change missation looking statements today teen twentthousand 20, two application statement ex after dayat information not commion pro and ation prescriing decisation joining today President and mar commercial after point after day and and financial after following rep Mars cion, now mar Y President and C year Ning one Thank four joining our second quarter of 20 20 2, ninging in COUR ving 4, nine we are one of fect conies, mar by and ions. We development IE of new CL? Y 20 year uing continu to the able bres, we bres Su we Ion of's of the mar virment. Finally, we are the EC our of ING last child and we have number of cominging in 20 20, two and one we ue to on work conment of the second quarter and 20 20, two for our plement plcation exp able's to includ C in indcation four indication will be all 4, four ment B C, preventation of C ical. Our commercial trate be ation con and prescribers and D incl prescription. weare also study of's B, C ations, treatment including the more challengeing B cations. We indication and for the study twent Su expected 20 20, four potental 20 20, four our IE medical officeeeee we V more on GRS and the day first commercial CT's. We mem twent 20 1, one hundred prescript and of first AR. We are ex proers. We the miss ific in women and chie commercial officeeeee point prov more on our commercial plans going four work COUR. We second quar 20 20, two We more one cash, four challing time in the mar andwe continue to the first twent 20, four pected to our commercial C in twent 20, three we to complete our progrs to able ition 20, fiveing twent 20, four ment our financial officeeeee. We VID more on our exp and and we will 4, four sion. Now will thecourar chie commercial officeeeee point thank and morning 4, the morning D our commercial progress stated commercial oranization ING C first cus AR ecation. We Jo signific quarter quarter 20, 9% breact prescriptions in the second quarter. twotwentthousand 20, two measures TR cord expectcations including and new P prescrib and coverage we address three St are not five have Lear the last year our prescribers and cations. We more ining our commercial ization. We creed strate IM execation ated the prevention B C cation and C and more campaign plan four continue sixcess the signific o breact continue to the treatment C ation with cated of our will be the first and three and C on TR the bro indation. We expect broad exp crib conference long with Act them the last quarters we contin number BRE prescribers quarter over 20 hundred P prescrib breact represpresent CRE 20, 5% quarter over quarter focus to continue. Continue ING our prescribers. We continue to SP new prescribber breact with broad R? ation prescribed prescriptions continue to the last quarter we generated fif one hundred prescription in the second quarter 20 20, one represent 20, 9% first quarter 20 20, two the second quarter prescription by more execation AR focus ERS sou call and coun with our new H C P markeing campaign and ING C P and reion four H C continue to rep breact coun and other peers continue to over and CRE threerequen our pration and we will continue tract's. We focus on our ation cations ING for solation by the decad treatment and ishing breact stand for C second quar. twentthousand 20, six cover more than hundred nine nineillion commercial ort five represent six prespercent commercial ERS. We continue to AR our sou? ecation EFS, pport C prescribing breact. Women with plan continue to C the Val ue breact and FR? Ing enef, speci and fect ING C joining last call more H C P ation campaign. The campaign. The americ colle trions, collees and and ING President round ders C P TR have had and CRE? traf quarter two the ver? Ing of our H? C teen campaign four in threeat vent mar and generated over 20, four thousand's and seven hundred and nine pression in a high mar? Ur fir one H C? P year breact more one treatment for ation, argeted ation, ation ING one with Cross ulti an including and decig all ING ations two H C P, breack them. The new ation ver? izing incre traf breack and program C in three marks first four tration ation re we are C re more. We IM after year cent we mar Lo the top and treatment C C, C C having new prescription treatment ption action conformation on direct the campaign and ING Li top and cus Ion infaction and interest afr C and the? C quarter three we are executing .ation exciting new ation program continue power H? C P breact them. progrs breact will be plan D cast three Mon C expect Ed four point Ion fions to our targeted UD quarter three we are also part with national and form and stos cross countrythree place Act in stos national educ and power ERS C information. Ion treatments ING four over the coun procts ments will be place C over the coun inaction treatment and ERs H C P breact them. We also will be ING new patation year will be place on and progr partners targeted ING Mon ERS it over nine Ion pions and H? C breact treat Ion for themthe focus prescribber and ation effor conment the GR work of our national sou AC on focus on increasing the ED of our sou four EF and ING Act over the P year are learned H? C P ated prescribed Act and o ortunity sou continue to focus Val ue C? P we number of chararget and sou four thir 6, four ortunity and signific in C we continue to quarter over quarter. We have ING thir quarter plan and with the EF? Teen and our F? Ers and sou national sou leadter more work continue to D on our progress. Thank will over we continue ation of the develop bres four the treat. Prevention of more Form infe.ions year plement the four indication of ventation of cord C and re? Cent. We from the that applic cepted and we the arget C thir ation the study report and cent pres presented more inse four the study point. We 6, five point four cent of cations three with bres ING incl we pro or pect Ed treatment with's also stud signific C point including log ly in vent point percent of ation. All all treatment inseions's study continue to to not all inactions also recur of the C second ING indication will be the first and only the UN that indicated 4, both the threeatment C and the preventation of record B C one four's C three and we are dat to better the fin C .ations treatment P to in the study the ation to have B C time of ment C 3, three those on one 3, seven the ation treat included the main study prevention of those stationations that B C we three those Ro in the preventation of cord of the stud and all of bres treatment three hundred in study four patation included in the study and of sign C treatment all ment ters the resp one treatment bre.s we sevenvent Y one per Al Ion or mination of SCI ter also in the subjects in ation to twent also have treatment pon day bres report of 10 subjects percent the port in UD population nine with the pon in the C population included in tri's the of cpatations benef bres and con more with the pect of the C for compleicated more challenge ING incltwent ces. We at the recent three study that's C three ment for patations have at with including those specific population in new pro ation the study will pro 20, five UN to hundred fif subjects and weare arget to have dat from the second half twotwentthousand 20, four in ation. We continue pro in development programs the study. We re target ment of two hundred ject the study and we study CLO able complete of the four of all by first of next year. We will will four by the dat, the fin dat and the report of the fin fin at which GU Ed twentthousand 20, four the study four time line remind the and study BRE inpatations with and all fact four inseations the study continue patations. We are planning to complete study and the ailable dat by end of year. The number of ations may init projected. The dat from study even number of subject. We tion for development and study. We bres inpatations with C. the process progrress well more all the UN and many con Ed. We are C compleation of the study by end of next year. three the dat from the mar study, dat from study fourort of ation to 20 20, four we C first for indication year, also the compleation of the study with the four ulation of bres. We are the D en able cus Ion, the tental development four ulation. We are arget have ation end of year and will the to ment financial officeeeee incre proct reven from seven in the four